DOCSLIB.ORG

MRGPRX4 Is a G Protein-Coupled Receptor Activated by Bile Acids That May Contribute to Cholestatic Pruritus

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
MRGPRX4 Is a G Protein-Coupled Receptor Activated by Bile Acids That May Contribute to Cholestatic Pruritus MRGPRX4 is a G protein-coupled receptor activated by bile acids that may contribute to cholestatic pruritus James Meixionga, Chirag Vasavdaa, Solomon H. Snydera,b,c,1, and Xinzhong Donga,d,e,f,1 aSolomon H. Snyder Department of Neuroscience, The Johns Hopkins University School of Medicine, Baltimore, MD 21205; bDepartment of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD 21205; cDepartment of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD 21205; dDepartment of Dermatology, The Johns Hopkins University School of Medicine, Baltimore, MD 21205; eDepartment of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, MD 21205; and fHoward Hughes Medical Institute, The Johns Hopkins University School of Medicine, Baltimore, MD 21205 Contributed by Solomon H. Snyder, April 5, 2019 (sent for review February 26, 2019; reviewed by Hongzhen Hu and Gil Yosipovitch) Patients suffering from cholestasis, the slowing or stoppage of bile BA-induced itch is likely not TGR5 dependent in humans, a flow, commonly report experiencing an intense, chronic itch. scenario different from mice. Numerous pruritogens are up-regulated in cholestatic patient sera, Cholestatic pruritus is classified as nonhistaminergic itch. including bile acids (BAs). Acute injection of BAs results in itch in Cholestatic patients do not exhibit classic signs of histamine re- both mice and humans, and BA-modulating therapy is effective in lease, such as erythema or swelling (3). Moreover, antihistamines controlling patient itch. Here, we present evidence that human are ineffective in treating cholestatic pruritus, with only a few sensory neuron-expressed Mas-related G protein-coupled receptor patients reporting clinical improvement in their symptoms (3, X4 (MRGPRX4), an orphan member of the Mrgpr family of GPCRs, 2+ 19). The Mas-related family of G protein-coupled receptors is a BA receptor. Using Ca imaging, we determined that pathophy- (MRGPRs) are GPCRs that mediate nonhistaminergic itch. In siologically relevant levels of numerous BAs activated MRGPRX4. No mice, MRGPRs are expressed in small-diameter sensory neurons mouse Mrgpr orthologs were activated by BAs. To assess the in vivo that code exclusively for itch and not pain (20). Over the years, relevance of BA activation of MRGPRX4, we generated a humanized increasingly more members of the MRGPR family have been mouse with targeted expression of MRGPRX4 in itch-encoding sen- + identified as receptors for known pruritogens (21). sory neurons. BAs activated MRGPRX4 sensory neurons at higher In mice, there are 27 expressed Mrgprs, only a few of which NEUROSCIENCE levels compared with WT neurons. Compared with control animals, + have known ligands (22). In humans, there are eight expressed MRGPRX4 mice scratched more upon acute injection of BAs and in a – – model of cholestatic itch. Overall, these data suggest that targeting Mrgprs (MRGPRX1 X4 and -D G). MRGPRX1 and MRGPRD MRGPRX4 is a promising strategy for alleviating cholestatic itch. have been implicated in nonhistaminergic itch as receptors for pruritic compounds. MRGPRX1, -X3, -X4, -D, and -E are cholestasis | itch | pruritus | MRGPRX4 | bile acids expressed in human dorsal root ganglia (DRG) and trigeminal ganglia (TG), while MRGPRX2 has been detected in human – n the United States, hundreds of thousands of patients report mast cells (23 26). Recently, we have identified murine receptor Iexperiencing a severe, generalized pruritus (itch) due to cho- Mrgpra1 and human receptor MRGPRX4 as receptors for bili- lestasis, or the slowing or stoppage of bile flow. Cholestatic itch is rubin that may mediate a component of cholestatic itch (27). often nonresponsive to standard pharmacological treatments (1– 3) and instead requires physically removing the causative ob- Significance struction (such as gallstones), draining the bile, or transplanting the liver to alleviate itch (1, 4, 5). Because these procedures are Cholestatic itch is a debilitating symptom that affects hundreds often curative, the responsible pruritogens are hypothesized to of thousands of patients every year, drastically decreasing originate from the liver and bile. Numerous candidate pruri- patient quality of life. Additional therapeutic targets are togens are present in bile and up-regulated in cholestatic pa- needed, as current therapies are ineffective for many patients. tients, including opioids, lysophosphatidic acid, bilirubin, and In recent years, the Mas-related G protein-coupled receptor bile acids (BAs). Therapies targeting these mechanisms, such as (MRGPR) family of receptors has been linked to itch. Here, we opioid antagonists, rifampicin, and BA-binding resins like cho- determine that MRGPRX4 is specifically activated by numerous lestyramine, are frontline therapy for cholestatic itch (6–9). bile acids (BAs) up-regulated in cholestatic patient sera. To test the relevance of these findings in vivo, we generated human- BAs are amphipathic cholesterol derivatives synthesized in + ized mice expressing MRGPRX4 in sensory neurons. MRGPRX4 liver. BAs have previously defined roles as detergents, hormones, humanized mice display higher levels of itch in response to and antiinflammatory agents (10–13). Primary BA synthesis aids injection of BAs and in a mouse model of cholestasis, indicating in biliary secretion of phospholipids, drugs, and toxins. In liver, that MRGPRX4 could play a role in cholestatic itch. BAs are conjugated with taurine or glycine for biliary secretion. Secreted BAs can be reabsorbed in the ileum and retrogradely Author contributions: J.M. designed research; J.M. and C.V. performed research; J.M. and transported to liver where they inhibit synthesis in an inhibitory C.V. analyzed data; J.M., C.V., S.H.S., and X.D. wrote the paper; and S.H.S. and X.D. feedback loop. In cholestatic patients, BAs accumulate in both supervised the research. serum and tissue because bile flow is abrogated. Reviewers: H.H., Washington University School of Medicine in St. Louis; and G.Y., Univer- BAs are pruritic as injecting BAs in humans evokes itch (14, sity of Miami Miller School of Medicine. 15). In mice, TGR5, a G protein-coupled receptor (GPCR) with Conflict of interest statement: J.M. is a consultant for Escient Pharmaceuticals, a company focused on developing small molecule inhibitors for MRGPRs. X.D. is a co-founder of micromolar affinity toward BAs (16, 17), is expressed in itch Escient Pharmaceuticals. −/− sensory neurons (10). TGR5 mice scratched less in response Published under the PNAS license. to injection of multiple activating BAs, indicating that the re- 1To whom correspondence may be addressed. Email: [email protected] or xdong2@jhmi. ceptor mediates a component of acute BA-associated itch (10). edu. However, recent clinical trials have found that TGR5-specific This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. agonists do not elicit pruritus, suggesting that activating TGR5 1073/pnas.1903316116/-/DCSupplemental. alone is not sufficient to evoke itch in humans (18). Accordingly, www.pnas.org/cgi/doi/10.1073/pnas.1903316116 PNAS Latest Articles | 1of6 Downloaded by guest on September 25, 2021 + Another published MRGPRX4 agonist, nateglinide, is a clini- MRGPRX4-induced Ca2 signal was dependent on intracellular + cally approved type 2 diabetes drug that causes itch as a prom- Ca2 stores. Previous studies have identified MRGPRX4 as be- inent side effect (28, 29), further implicating MRGPRX4 as an ing Gαq linked (27, 29). In line with this, DCA-associated 2+ itch receptor. In this study, we screened major bile constituents Ca flux appears to be similarly Gαq linked, since both the against a panel of both mouse and human MRGPRs. From this Gαq inhibitor, YM254890, and the PLC inhibitor, U73122, + screen, we determined that numerous BAs specifically activated inhibited Ca2 signal (Fig. 1 G and H). MRGPRX4. Of all mouse and human receptors tested, BAs only Of the BAs tested, DCA and ursodeoxycholic acid (UDCA) activated MRGPRX4. Using newly generated humanized mice displayed the highest potency in terms of MRGPRX4-associated + in which we express MRGPRX4 selectively in itch-sensing neu- Ca2 signal (Fig. 1C and SI Appendix, Fig. S1F). Both DCA and rons, we demonstrated that MRGPRX4 contributed to the BA- UDCA had EC50sof∼5 μM, similar to their activity toward induced component of cholestatic itch. previously published receptors like TGR5 (17). Unlike TGR5, however, MRGPRX4 exhibited a larger range of potency for Results various BAs. For example, cholic acid (CA) displayed much In liver hepatocytes, cholesterol is metabolized via cytochrome lower potency against MRGPRX4 (EC50 ∼430 μM), well outside P450 (CYP) to primary BAs (Fig. 1A). Primary BAs are sub- physiologic range. In contrast, the EC50 of CA toward TGR5 is sequently metabolized to other BAs, after which they are con- ∼10 μM (17). jugated to either glycine or taurine for more efficient biliary Primary bile acids can be conjugated to either glycine or taurine secretion. In the intestine, bacteria metabolize BAs to form to form water-soluble bile salts. We tested three tauro-conjugated secondary BAs, which can return to the bloodstream and liver bile acids, tauro-DCA (TDCA), tauro-CDCA (TCDCA), and through enterohepatic circulation (Fig. 1A). We recently iden- tauro-cholic acid (TCA) against MRGPRX4. All conjugated bile tified MRGPRX4 as a bilirubin receptor that may contribute
Load more

Recommended publications
  • Edinburgh Research Explorer
    Edinburgh Research Explorer International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list Citation for published version: Davenport, AP, Alexander, SPH, Sharman, JL, Pawson, AJ, Benson, HE, Monaghan, AE, Liew, WC, Mpamhanga, CP, Bonner, TI, Neubig, RR, Pin, JP, Spedding, M & Harmar, AJ 2013, 'International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands', Pharmacological reviews, vol. 65, no. 3, pp. 967-86. https://doi.org/10.1124/pr.112.007179 Digital Object Identifier (DOI): 10.1124/pr.112.007179 Link: Link to publication record in Edinburgh Research Explorer Document Version: Publisher's PDF, also known as Version of record Published In: Pharmacological reviews Publisher Rights Statement: U.S. Government work not protected by U.S. copyright General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 02. Oct. 2021 1521-0081/65/3/967–986$25.00 http://dx.doi.org/10.1124/pr.112.007179 PHARMACOLOGICAL REVIEWS Pharmacol Rev 65:967–986, July 2013 U.S.
    [Show full text]
  • G Protein-Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. British Journal of Pharmacology (2015) 172, 5744–5869 THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: G protein-coupled receptors Stephen PH Alexander1, Anthony P Davenport2, Eamonn Kelly3, Neil Marrion3, John A Peters4, Helen E Benson5, Elena Faccenda5, Adam J Pawson5, Joanna L Sharman5, Christopher Southan5, Jamie A Davies5 and CGTP Collaborators 1School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK, 2Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK, 3School of Physiology and Pharmacology, University of Bristol, Bristol, BS8 1TD, UK, 4Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK, 5Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/ 10.1111/bph.13348/full. G protein-coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading.
    [Show full text]
  • 1 Supplemental Material Maresin 1 Activates LGR6 Receptor
    Supplemental Material Maresin 1 Activates LGR6 Receptor Promoting Phagocyte Immunoresolvent Functions Nan Chiang, Stephania Libreros, Paul C. Norris, Xavier de la Rosa, Charles N. Serhan Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA. 1 Supplemental Table 1. Screening of orphan GPCRs with MaR1 Vehicle Vehicle MaR1 MaR1 mean RLU > GPCR ID SD % Activity Mean RLU Mean RLU + 2 SD Mean RLU Vehicle mean RLU+2 SD? ADMR 930920 33283 997486.5381 863760 -7% BAI1 172580 18362 209304.1828 176160 2% BAI2 26390 1354 29097.71737 26240 -1% BAI3 18040 758 19555.07976 18460 2% CCRL2 15090 402 15893.6583 13840 -8% CMKLR2 30080 1744 33568.954 28240 -6% DARC 119110 4817 128743.8016 126260 6% EBI2 101200 6004 113207.8197 105640 4% GHSR1B 3940 203 4345.298244 3700 -6% GPR101 41740 1593 44926.97349 41580 0% GPR103 21413 1484 24381.25067 23920 12% NO GPR107 366800 11007 388814.4922 360020 -2% GPR12 77980 1563 81105.4653 76260 -2% GPR123 1485190 46446 1578081.986 1342640 -10% GPR132 860940 17473 895885.901 826560 -4% GPR135 18720 1656 22032.6827 17540 -6% GPR137 40973 2285 45544.0809 39140 -4% GPR139 438280 16736 471751.0542 413120 -6% GPR141 30180 2080 34339.2307 29020 -4% GPR142 105250 12089 129427.069 101020 -4% GPR143 89390 5260 99910.40557 89380 0% GPR146 16860 551 17961.75617 16240 -4% GPR148 6160 484 7128.848113 7520 22% YES GPR149 50140 934 52008.76073 49720 -1% GPR15 10110 1086 12282.67884
    [Show full text]
  • G Protein‐Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: G protein-coupled receptors. British Journal of Pharmacology (2019) 176, S21–S141 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors Stephen PH Alexander1 , Arthur Christopoulos2 , Anthony P Davenport3 , Eamonn Kelly4, Alistair Mathie5 , John A Peters6 , Emma L Veale5 ,JaneFArmstrong7 , Elena Faccenda7 ,SimonDHarding7 ,AdamJPawson7 , Joanna L Sharman7 , Christopher Southan7 , Jamie A Davies7 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Victoria 3052, Australia 3Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK 4School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK 5Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK 6Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK 7Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website.
    [Show full text]
  • Unlocking the Non-Ige-Mediated Pseudo-Allergic Reaction Puzzle with Mas-Related G-Protein Coupled Receptor Member X2 (MRGPRX2)
    cells Review Unlocking the Non-IgE-Mediated Pseudo-Allergic Reaction Puzzle with Mas-Related G-Protein Coupled Receptor Member X2 (MRGPRX2) Mukesh Kumar, Karthi Duraisamy and Billy-Kwok-Chong Chow * School of Biological Sciences, The University of Hong Kong, Pokfulam Road, Hong Kong, China; [email protected] (M.K.); [email protected] (K.D.) * Correspondence: [email protected]; Tel.: +852-2299-0850; Fax: +852-2559-9114 Abstract: Mas-related G-protein coupled receptor member X2 (MRGPRX2) is a class A GPCR ex- pressed on mast cells. Mast cells are granulated tissue-resident cells known for host cell response, allergic response, and vascular homeostasis. Immunoglobulin E receptor (Fc"RI)-mediated mast cell activation is a well-studied and recognized mechanism of allergy and hypersensitivity reac- tions. However, non-IgE-mediated mast cell activation is less explored and is not well recognized. After decades of uncertainty, MRGPRX2 was discovered as the receptor responsible for non-IgE- mediated mast cells activation. The puzzle of non-IgE-mediated pseudo-allergic reaction is unlocked by MRGPRX2, evidenced by a plethora of reported endogenous and exogenous MRGPRX2 ag- onists. MRGPRX2 is exclusively expressed on mast cells and exhibits varying affinity for many molecules such as antimicrobial host defense peptides, neuropeptides, and even US Food and Drug Administration-approved drugs. The discovery of MRGPRX2 has changed our understanding of mast cell biology and filled the missing link of the underlying mechanism of drug-induced MC degranulation and pseudo-allergic reactions. These non-canonical characteristics render MRGPRX2 Citation: Kumar, M.; Duraisamy, K.; Chow, B.-K.-C.
    [Show full text]
  • MRGPRX4 Is a Novel Bile Acid Receptor in Cholestatic Itch Huasheng Yu1,2,3, Tianjun Zhao1,2,3, Simin Liu1, Qinxue Wu4, Omar
    bioRxiv preprint doi: https://doi.org/10.1101/633446; this version posted May 9, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 MRGPRX4 is a novel bile acid receptor in cholestatic itch 2 Huasheng Yu1,2,3, Tianjun Zhao1,2,3, Simin Liu1, Qinxue Wu4, Omar Johnson4, Zhaofa 3 Wu1,2, Zihao Zhuang1, Yaocheng Shi5, Renxi He1,2, Yong Yang6, Jianjun Sun7, 4 Xiaoqun Wang8, Haifeng Xu9, Zheng Zeng10, Xiaoguang Lei3,5, Wenqin Luo4*, Yulong 5 Li1,2,3* 6 7 1State Key Laboratory of Membrane Biology, Peking University School of Life 8 Sciences, Beijing 100871, China 9 2PKU-IDG/McGovern Institute for Brain Research, Beijing 100871, China 10 3Peking-Tsinghua Center for Life Sciences, Beijing 100871, China 11 4Department of Neuroscience, Perelman School of Medicine, University of 12 Pennsylvania, Philadelphia, PA 19104, USA 13 5Department of Chemical Biology, College of Chemistry and Molecular Engineering, 14 Peking University, Beijing 100871, China 15 6Department of Dermatology, Peking University First Hospital, Beijing Key Laboratory 16 of Molecular Diagnosis on Dermatoses, Beijing 100034, China 17 7Department of Neurosurgery, Peking University Third Hospital, Peking University, 18 Beijing, 100191, China 19 8State Key Laboratory of Brain and Cognitive Science, CAS Center for Excellence in 20 Brain Science and Intelligence Technology (Shanghai), Institute of Biophysics, 21 Chinese Academy of Sciences, Beijing, 100101, China 22 9Department of Liver Surgery, Peking Union Medical College Hospital, Chinese bioRxiv preprint doi: https://doi.org/10.1101/633446; this version posted May 9, 2019.
    [Show full text]
  • The Multifaceted Mas-Related G Protein-Coupled Receptor Member X2 in Allergic Diseases and Beyond
    International Journal of Molecular Sciences Review The Multifaceted Mas-Related G Protein-Coupled Receptor Member X2 in Allergic Diseases and Beyond Paola Leonor Quan 1,* , Marina Sabaté-Brescó 1,2,† , Yanru Guo 3,4, Margarita Martín 3,4,† and Gabriel Gastaminza 1,2,† 1 Department of Allergy and Clinical Immunology, Clínica Universidad de Navarra, 31008 Pamplona, Spain; [email protected] (M.S.-B.); [email protected] (G.G.) 2 Navarra Health Research Institute (Instituto de Investigación Sanitaria de Navarra) (IdiSNA), 31008 Navarra, Spain 3 Biochemistry Unit, Biomedicine Department, Faculty of Medicine, University of Barcelona, 08036 Barcelona, Spain; [email protected] (Y.G.); [email protected] (M.M.) 4 Laboratory of Clinical and Experimental Respiratory Immunoallergy, IDIBAPS, 08036 Barcelona, Spain * Correspondence: [email protected] † Research Network: Research Network on Asthma, Drug Adverse Reactions and Allergy (Red de Investigación en Asma, Reacciones Adversas a Fármacos y Alergia) (ARADyAL), Spain. Abstract: Recent research on mast cell biology has turned its focus on MRGPRX2, a new member of the Mas-related G protein-coupled subfamily of receptors (Mrgprs), originally described in noci- ceptive neurons of the dorsal root ganglia. MRGPRX2, a member of this group, is present not only in neurons but also in mast cells (MCs), specifically, and potentially in other cells of the immune system, such as basophils and eosinophils. As emerging new functions for this receptor are studied, a variety of both natural and pharmacologic ligands are being uncovered, linked to the ability to induce Citation: Quan, P.L.; Sabaté-Brescó, receptor-mediated MC activation and degranulation. The diversity of these ligands, characterized in M.; Guo, Y.; Martín, M.; Gastaminza, their human, mice, or rat homologues, seems to match that of the receptor’s interactions.
    [Show full text]
  • A Pharmacological Interactome Platform for Discovery of Pain Mechanisms and Targets
    bioRxiv preprint doi: https://doi.org/10.1101/2020.04.14.041715; this version posted April 16, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. A pharmacological interactome platform for discovery of pain mechanisms and targets Short title: A pharmacological interactome for pain target identification Andi Wangzhou1, Candler Paige1, Sanjay V Neerukonda1, Gregory Dussor1, Pradipta R Ray1,#, Theodore J Price1,#,* 1The University of Texas at Dallas, School of Behavioral and Brain Sciences and Center for Advanced Pain Studies, 800 W Campbell Rd. Richardson, TX, 75080, USA # corresponding authors [email protected] and [email protected] * lead contact Funding: NIH grants NS113457 (CP), NS065926 (TJP) and NS102161 (TJP) The authors declare no conflicts of interest. Author Contributions: Conceived of the Project: GD, PRR and TJP Performed Experiments: AW, CP, SVN and PRR Supervised Experiments: GD, PRR and TJP Analyzed Data: AW, CP and PRR Drew Figures: AW, and CP Wrote and Edited Manuscript: AW, CP, GD, PRR and TJP All authors approved the final version of the manuscript. Acknowledgements: The authors would like to thank Drs. James Hockley and Ewan St. John Smith for help with the colonic single neuron sequencing data, Dr. Brian Gulbransen and lab for help with the enteric glia TRAP data and Dr. Zhenyu Xuan for clarifying TCGA metadata formats. We thank all the authors of the papers from which we used their sequencing data for their exemplary transparency in sharing the details of their work with us.
    [Show full text]
  • Mediators and Receptors of Chronic Itch in Primates and Humans
    MEDIATORS AND RECEPTORS OF CHRONIC ITCH IN PRIMATES AND HUMANS A Dissertation Submitted to the Temple University Graduate Board In Partial Fulfillment of the Requirements for the Degree DOCTOR OF PHILOSOPHY by Leigh Ann Nattkemper December 2015 Examining Committee Members: Gil Yosipovitch, MD, Advisory Chair, Department of Dermatology Mary Barbe, PhD, Department of Anatomy and Cell Biology Liselotte Jensen, PhD, Department of Microbiology and Immunology Alan Cowan, PhD, Department of Pharmacology Mark Hoon, PhD, External Member, National Institutes of Health (NIDCR) © Copyright 2015 by Leigh Nattkemper All Rights Reserved ii ABSTRACT Chronic itch has a significant impact on quality of life for millions of patients worldwide, on a level comparable to that of chronic pain. Yet, although there are a host of effective drugs available for pain, there are no therapies that specifically target chronic itch. Current experimental approaches to investigate the pathogenesis of chronic pruritus and to test novel therapeutic agents are largely limited to rodent models. However, rodent models display significant dermatological, neurophysiological, and immunological differences from humans with chronic itch. The disadvantages of the current rodent paradigms call for the design of a valid primate model of chronic itch. For four years, we have monitored scratching behavior in a primate colony (n=35) of Cynomolgus macaques ( Macaca fascicularis ) suffering from idiopathic chronic itch. By comparing molecular and genetic analyses of the primates’ skin to their quantified scratching behavior, we attempted to characterize the underlying mechanisms of chronic itch in this model. Furthermore, the expression of itch-related proteins was examined in both the primate model and in humans with pruritic diseases.
    [Show full text]
  • MRGPRX2 Activation by Rocuronium: Insights from Studies with Human Skin Mast Cells and Missense Variants
    cells Communication MRGPRX2 Activation by Rocuronium: Insights from Studies with Human Skin Mast Cells and Missense Variants Chalatip Chompunud Na Ayudhya 1, Aetas Amponnawarat 1, Saptarshi Roy 1, Carole A. Oskeritzian 2 and Hydar Ali 1,* 1 Department of Basic and Translational Sciences, University of Pennsylvania School of Dental Medicine, Philadelphia, PA 19104, USA; [email protected] (C.C.N.A.); [email protected] (A.A.); [email protected] (S.R.) 2 Department of Pathology, Microbiology and Immunology, University of South Carolina School of Medicine, Columbia, SC 20209, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-215-573-1993 Abstract: Perioperative hypersensitivity (POH) to the neuromuscular blocking drug (NMBD) rocuro- nium was previously thought to be IgE and mast cell (MC)-mediated. However, the recent seminal observation that rocuronium induces degranulation in murine peritoneal MCs (PMCs) via Mas- related G protein-coupled receptor B2 (MrgprB2) led to the idea that POH to this drug involves the activation of MRGPRX2 (human ortholog of MrgprB2). Furthermore, based on the demonstration that a patient with POH to rocuronium displayed three missense mutations (M196I, L226P and L237P) in MRGPRX2’s transmembrane domains, it was proposed that this hypersensitivity reaction resulted from aberrant activation of this receptor. We found that rocuronium at 20 µg/mL caused degranulation in mouse PMCs via MrgprB2 but required at least 500 µg/mL to induce degranulation in human MCs via MRGPRX2. Furthermore, RBL-2H3 cells transiently expressing M196I, L226P and L237P variants did not display enhanced degranulation in response to rocuronium when compared to the wild-type receptor.
    [Show full text]
  • G Protein‐Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: G protein-coupled receptors. British Journal of Pharmacology (2019) 176, S21–S141 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors Stephen PH Alexander1 , Arthur Christopoulos2 , Anthony P Davenport3 , Eamonn Kelly4, Alistair Mathie5 , John A Peters6 , Emma L Veale5 ,JaneFArmstrong7 , Elena Faccenda7 ,SimonDHarding7 ,AdamJPawson7 , Joanna L Sharman7 , Christopher Southan7 , Jamie A Davies7 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Victoria 3052, Australia 3Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK 4School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK 5Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK 6Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK 7Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website.
    [Show full text]
  • RT² Profiler PCR Array (384-Well Format) Mouse G Protein Coupled Receptors 384HT
    RT² Profiler PCR Array (384-Well Format) Mouse G Protein Coupled Receptors 384HT Cat. no. 330231 PAMM-3009ZE For pathway expression analysis Format For use with the following real-time cyclers RT² Profiler PCR Array, Applied Biosystems® models 7900HT (384-well block), Format E ViiA™ 7 (384-well block); Bio-Rad CFX384™ RT² Profiler PCR Array, Roche® LightCycler® 480 (384-well block) Format G Description The Mouse G Protein Coupled Receptors 384HT RT² Profiler™ PCR Array profiles the expression of a comprehensive panel of 370 genes encoding the most important G Protein Coupled Receptors (GPCR). GPCR regulate a number of normal biological processes and play roles in the pathophysiology of many diseases upon dysregulation of their downstream signal transduction activities. As a result, they represent 30 percent of the targets for all current drug development. Developing drug screening assays requires a survey of which GPCR the chosen cell-based model system expresses, to determine not only the expression of the target GPCR, but also related GPCR to assess off-target side effects. Expression of other unrelated GPCR (even orphan receptors whose ligand are unknown) may also correlate with off-target side effects. The ligands that bind and activate the receptors on this array include neurotransmitters and neuropeptides, hormones, chemokines and cytokines, lipid signaling molecules, light-sensitive compounds, and odorants and pheromones. The normal biological processes regulated by GPCR include, but are not limited to, behavioral and mood regulation (serotonin, dopamine, GABA, glutamate, and other neurotransmitter receptors), autonomic (sympathetic and parasympathetic) nervous system transmission (blood pressure, heart rate, and digestive processes via hormone receptors), inflammation and immune system regulation (chemokine receptors, histamine receptors), vision (opsins like rhodopsin), and smell (olfactory receptors for odorants and vomeronasal receptors for pheromones).
    [Show full text]